B
K polyomavirus (BKPyV) was first isolated from the urine of a renal allograft recipient in 1971 and was subsequently identified as a member of the small DNA tumor virus family (1) . BKPyV infection is ubiquitous, and seroconversion of up to 90% of the world's population by the age of 10 suggests that BKPyV transmission takes place during early childhood (2, 3) . BKPyV primary infection is asymptomatic and persists latently in the kidney of immunocompetent individuals (4) . Reactivation occurs under immune-suppressed conditions, such as those experienced by patients receiving organ transplants and patients infected with HIV (5) . BKPyV reactivation among kidney transplant patients has been associated with BKPyV nephropathy (BKN), which is by far the most significant complication among renal transplant patients (6) (7) (8) .
The BKPyV genome (5 kb) is divided into three major components: the early region, the late region, and the bidirectional viral promoter, also known as the noncoding control region (NCCR). The NCCR is the major determinant of in vitro replication (9) and is arbitrarily divided into five block sequences: O (142 bp), P (68 bp), Q (39 bp), R (63 bp), and S (63 bp). The blocks contain the origin of DNA replication and an array of transcription factor binding sites (TFBS) (10) (11) (12) (13) . The late region encodes the agnoprotein and the structural proteins VP1, VP2 and VP3 (4, 14) . The early BKPyV genome region encodes the nonstructural viral proteins: large, small, and mini-T antigen. Large T antigen (Tag) is critical for the viral life cycle and drives the host cell into the S phase (4, (15) (16) (17) . Viral DNA synthesis is initiated by Tag's helicase activity, which unwinds the origin of replication within the viral NCCR promoter (4) and subsequently recruits DNA synthetic machinery (5) . As the major BKPyV transforming viral oncoprotein, Tag interacts with both pRb and p53, instigating deregulated cell growth. The Tag transformation potential is linked to the p53-binding domain located near the carboxy terminus of the protein (18) . Upon initiation of DNA replication, Tag induces late viral gene expression and represses early gene expression (19) .
Given its historic link to renal pathogenesis, BKPyV has been considered a kidney-tropic virus. Data however suggest a connection between BKPyV and the oral compartment. Both respiratory (5) and fecal-oral (20) routes have been suggested as likely transmission pathways. BKPyV DNA has been detected in tonsillar biopsy specimens from immunocompetent children (21) (22) (23) and nasopharyngeal aspirates of immunocompromised and immunocompetent individuals (children and adults) (24) . Finally, our group has suggested a potential link between BKPyV and the oral malady HIV-associated salivary gland disease (HIVSGD) (25, 26) .
HIVSGD is among the most important HIV/AIDS-associated lesions (27) . HIVSGD pathogenesis is not well understood, and present treatment strategies focus solely on symptom alleviation (25) . HIVSGD is characterized by salivary gland enlargement and damage that incites xerostomia (28) (29) (30) (31) . HIVSGD diagnosis has been tied to an increased risk of lymphoma development in HIVinfected individuals (32) . Finally, affected patients may suffer stigma as HIVSGD's outward appearance suggests HIV infection. As for HIVSGD etiology, molecular evidence has previously established an association between polyomaviruses (PyV) and salivary gland pathology. Rodent models demonstrated that PyV injection resulted in salivary gland tumors in mice (33) . In vivo, HIVSGD patients shed 20-fold-higher levels of BKPyV in throat wash (TW) and plasma (viremia) than HIV-positive patients without HIVSGD and HIV-negative individuals (25) . Moreover, our group has demonstrated successful replication of a BKPyV laboratory strain in human salivary gland cell lines (HSG and HSY) in vitro (26) . While contemporary advances have allowed efficient in vitro cultivation of archetype BKPyV in kidney cells (providing Tag in trans [34] ), studies analyzing clinical BKPyV isolates have been limited and kidney focused and have not assessed salivary gland infection (9, (35) (36) (37) (38) . Molecular evidence demonstrates that the in vivo replication compartments of urine-and plasma-derived BKPyV are distinct (39, 40) . Similarly, the salivary gland may provide an additional BKPyV replication compartment in HIVSGD (41) .
In the present study, HIVSGD-derived BKPyV underwent successful replication in human salivary gland (HSG) cells, providing proof of concept that salivary glands of HIVSGD patients may be replication competent. We further compared the replication potential of TW-derived BKPyV clinical isolates to those of urine-and laboratory-derived BKPyV in HSG cells and in kidney cells (Vero). The replication potential of the clinical isolates HIVSGD-1 and HIVSGD-2 differed greatly despite the two isolates bearing the same NCCR architecture (OPQPQQS) and their genomes differing by only three nucleotides. The replication inefficiency of HIVSGD-2 was likely caused by the introduction of a stop codon that produced a truncated Tag mutant. Interestingly, HIVSGD-1 BKPyV encoded full-length Tag, replicated efficiently, and displayed preferential tropism for salivary gland cells over kidney cells, as suggested by quantitation of infectious virus.
MATERIALS AND METHODS
Patient information and sample collection. HIVSGD-positive individuals from The University of North Carolina at Chapel Hill (UNC) hospital dental clinic were selected for throat wash (TW) collection under institutional review board (IRB)-approved study guidelines. Urine samples from HIV-negative patients were kindly donated and collected under the supervision of V. Nickeleit at UNC Hospitals. Patient samples were centrifuged and DNase treated, and DNA was isolated via the Qiagen DNeasy kit, as described by the manufacturer.
BKPyV NCCR sequencing. The BKPyV NCCR was PCR amplified (Vent polymerase; New England BioLabs, Inc.) with primers BKPyVTU1F and BKPyVTU1R (37) from patient sample DNA, and the products were subsequently sequenced by Genewiz, Research Triangle Park, NC. NCCR amplification and sequencing was repeated a minimum of three times per patient sample. The resulting NCCR nucleotide sequence was analyzed and aligned by the Vector NTI program. Vector NTI identified the block motifs with a minimum similarity of 70% to original block sequences (10) .
wg BKPyV cloning. Whole-genome (wg) BKPyVs, including the naturally occurring BamHI restriction fragment recognition sites, were PCR amplified from clinical samples with primers BKPyVWGF (VP1 Forward, 5=-GCGGGATCCAGATGAAAACCTTAGG-3=) and BKPyVWGR (VP1 Reverse, 5=-GCGGGATCCCCCATTTCTGG-3=), using the Expand Long Range dNTPack (Roche) as described by the manufacturer. Amplified wg BKPyV products were purified by the QIAquick PCR purification kit (Qiagen), as described by the manufacturer. Purified HIVSGD-2 and U1 wg BKPyV DNA was cloned via the TOPO TA cloning kit (Invitrogen) as described by the manufacturer. Purified HIVSGD-1 DNA and pUC18 vector (2.6 kb) from Stratagene were digested separately with restriction endonuclease BamHI, isolated, ligated via T4 DNA ligase (BioLabs). DH5␣ bacterial cells (Invitrogen) were transformed with the HIVSGD-1, HIVSGD-2, and MM ligation products. All bacterium-derived constructs were isolated via QIAfilter plasmid Midi kit (Qiagen) after 24 h of incubation at 37°C.
Virus, transfection, and infection conditions. The clinical BKPyV strains cloned by us were HIVSGD-1, HIVSGD-2, and U1. The commercially available infectious BKPyV was VR837 (ATCC). The laboratoryderived Dunlop BKPyV clone was kindly donated by Michael J. Imperiale. The laboratory-derived MM (ATCC 45026) BKPyV clone (42) is commercially available. Interestingly, the MM BKPyV NCCR and Tag sequencing results obtained in this study were not homologous with previously published sequence (GenBank accession no. V01109).
BKPyV transfection. Cloned BKPyV was cut out of its respective backbones by overnight (37°C) incubation with BamHI endonuclease; HIVSGD-1 (pUC18), HIVGD-2 (pCR2.1), U1 (pCR2.1) and MM (ATCC 45026) (pBR322). wg BKPyV cloned into pCR2.1 was digested with endonuclease Taq1a for an additional 3 h at 65°C. wg BKPyV cloned into pBR322 was digested with endonuclease BsAa1 for an additional 3 h at 37°C. All digested samples were run on a 2% ethidium bromide (EtBr) agarose gel, and 5-kb bands were isolated in order to obtain wg BKPyV. wg BKPyV DNA was purified via the QIAquick gel extraction kit (Qiagen), as instructed by the manufacturer, and religated via T4 DNA ligase (BioLabs) overnight at 16°C. Episomal viral DNA was subsequently purified via phenol-chloroform. Single layers of HSG and Vero cells were passaged by trypsinization (ϳ15 min), resuspended in 2% fetal bovine serum (FBS) and 1% penicillin-streptomycin culture medium, and subsequently seeded at ϳ30% confluence. Episomal BKPyV was introduced into the cells via lipid-mediated gene delivery, using TransIT-LU1 (Mirus) according to the manufacturer's protocol. Medium was changed 48 h posttransfection (p.t.). Media and cells were collected at different time points for further analysis.
Infection. Equal amounts of infectious clinical and laboratory strain BKPyV (determined via fluorescent focus assay [FFA]) were used for infection of HSG and Vero cells-illustrated in part 2 of the in vitro model shown in Fig. 4 . Supernatants of transfected HSG cells carrying infectious BKPyV were passed through 0.45-m-pore filters and added to fresh HSG and Vero cells.
Cell culture. Human submandibular salivary gland epithelial cells (HSG cells) from adenocarcinoma (43) were obtained from B. Baum (NIH) and maintained in McCoy's 5A medium (Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma) and 1% penicillin-streptomycin (P/S) (Gibco). African green monkey kidney epithelial cells (Vero cells), were obtained from the American Type Culture Collection (ATCC), maintained in Dulbecco's minimal essential medium (DMEM) (Sigma) supplemented with 10% FBS and 1% P/S. Both cell lines were incubated in humidified atmosphere at 37°C and 5% CO 2 .
Reporter construct formation. Primers BKPyVTU1F and BKPyVTU1R (37) were used to amplify the BKPyV NCCR with flanking SacI restriction fragment recognition sites via PCR (Vent polymerase; New England BioLabs, Inc.). Amplified DNA products were purified by QIAquick PCR purification kit (Qiagen), as described by manufacturer. Purified DNA and pGL3-Basic vector (5 kb) from Promega were digested separately with restriction endonuclease SacI, isolated, and ligated via T4 DNA ligase (BioLabs). DH5␣ bacterial cells (Invitrogen) were transformed with products, and constructs were isolated via the QIAfilter plasmid Midi kit (Qiagen) after 24 h of incubation at 37°C.
BKPyV NCCR promoter activity. HIVSGD-1 and HIVSGD-2 BKPyV NCCR promoter activities were measured with and without the presence of wild-type large Tag in HSG cells via the luciferase (Luc) reporter assay (pGL3 vectors; Promega). Cloned reporter constructs (1 g) were transfected into HSG cells via lipid-mediated gene delivery, using TransIT-LU1 (Mirus) according to the manufacturer's protocol. pCDNA RFP (red fluorescent protein) was cotransfected along with or without Tag (0.5 g) expression plasmid (in pCMV myc; kindly provided by L. Jeffers). The Tag expression plasmid encoded VR837 BKPyV-derived full-length wildtype large Tag. Cells were collected from each treatment at 48 h according to the Promega luciferase assay protocol. Luc activities of the HIVSGD clones, pGL3 control vector (positive control [not shown]), and pGL3-Basic vector (negative control) were measured in a microplate format by the LMAX luminometer (Molecular Devices). HIVSGD Luc activity was normalized to pGL3-Basic.
FFA. Vero cells (50% confluence) were infected with various volumes of filtered (0.45-m pore) supernatant from transfected HSG cells and incubated over 4 days. Where low levels of virus were present, higher volumes were utilized in order to attain infection. These differences in volumes used for Vero cell infection are accounted for in calculations of fluorescence-forming units (FFU)/l (44) . Vero cells were fixed in 50:50 methanol-acetone, air dried, and stored at Ϫ80°C overnight 4 days postinfection (p.i.). Cells were rehydrated with phosphate-buffered saline (PBS) the next day and incubated with anti-JC/BK polyomavirus primary antibody NCL JCBK (Novocastra, Leica) at a 1:10 dilution in PBS for 30 min at 37°C and 30 min at room temperature (RT). The secondary antibody, goat anti-mouse-Alexa Fluor 488 (Life Technologies) conjugate at a 1:100 dilution in PBS, was added for 1 h at RT after the cells had been washed twice with PBS. Cells were washed with PBS prior to addition of DAPI (4=,6-diamidino-2-phenylindole)-DNA stain (1:10,000) and fluorescence microscopy analysis (Olympus IX81). BKPyV-infected cells were counted at a ϫ20 magnification for a minimum of 10 fields per dish, and FFU were calculated as described in reference 44 . FFU values were graphed for each treatment and are depicted as FFU/l or FFU/l ϩ 1 in order to transform the zero values for the log 10 -based y axis.
BKPyV DNA detection via Southern blot hybridization. BKPyV episomes were transfected (see above for BKPyV DNA and transfection details) into HSG cells at the following concentrations: 0.39 g Dunlop, 0.45 g U1, 0.72 g HIVSGD-1, 0.9 g MM, and 0.9 g pcDNA3 DNA. Differential amounts of DNA were transfected for the DpnI resistance assay. Hence, this assay was not intended to compare BKPyV replication levels. All succeeding experiments were intended to evaluate relative viral replication levels, and transfections were done with equal amounts of BKPyV DNA. Low-molecular-weight DNA was isolated from HSG cells 6 days p.t. by a previously described modified Hirt method (45) , digested by endonucleases Sau3a and DpnI, electrophoresed on a 7% agarose gel, and transferred onto a SuPerCharge (SPC) membrane by the Whatman Nytran SPC Turbo blotter (General Electric), as described by the manufacturer. Membrane-associated BKPyV DNA was detected by hybridization to randomly primed wg MM BKPyV (ATCC 45026) 32 P-labeled DNA probe and exposed to film (Kodak). The expected MM BKPyV DNA band sizes according to mapped DpnI/Sau3a cut sites were 1,522, 681, 529, 451, 432, 346, 294, 230, 216, 129, and 116 bp.
Encapsidated viral DNA isolation and qPCR amplification. Transfected and infected HSG and Vero cell supernatants were passed through 0.45-m-pore filters and DNase treated (Promega), removing debris/cells and nonencapsulated viral DNA, respectively. DNA was isolated using the QIAamp DNA blood minikit (Qiagen) as instructed by the manufacturer. Viral load (VL) was quantified via quantitative real-time PCR (qPCR) analysis with Roche LightCycler 480 SYBR green I master mix as a detector in the Roche Light Cycler 480 by using previously published primers for VP1 (46) . BKPyV plasmid, kindly donated by V. Nickeleit, was used to establish a standard curve and for subsequent quantification of encapsidated viral genomes present in the cellular supernatant.
TEM. Three milliliters of transfected, infected, or control HSG and Vero cell supernatant was spun at 13,000 rpm for 30 min at 4°C in order to remove cellular debris and then at 290,000 rpm for 1 h at 4°C by ultracentrifugation in order to concentrate BKPyV and decrease the suspension volume. Metal grids were subjected to purified supernatant and treated with 2% uralic acetate for negative staining. Virus was subsequently visualized via EM910 transmission electron microscopy (TEM) (Zeiss) utilizing a Gatan SC1000 camera.
Immunoblotting. Episomal BKPyV DNA (0.3 g) was transfected into HSG cells, and whole-cell lysates were harvested with 1% SDS lysis buffer 4 days posttransfection. Protein was quantified using the Bio-Rad protein assay, and equal amounts were electrophoresed on a 10% Bis-Tris polyacrylamide minigel (Invitrogen). Tag antibody PAb416 (Genetex) (1:200) in 5% nonfat dry milk in 0.1% Tween 20 -PBS (PBS-T) was used to detect Tag expression post-wg BKPyV transfection of HSG cells. cMyc-tagged Tag expression was detected via anti c-Myc antibody (Santa Cruz) (1:1,000) post-reporter construct transfection of HSG cells. Actin expression was detected via the (C-11)-R sc-1615-R antibody (Santa Cruz Biotechnology) (1:1,000) in 5% nonfat dry milk (as described above). Blots were washed in PBS-T three times for 10 min at RT and probed with a horseradish peroxidase-conjugated secondary antibody (Promega) (1: 10,000), exposed to SuperSignal West Pico chemiluminescent substrate (Thermo Scientific), and exposed to film (Kodak). Band intensity was measured via densitometry. Relative band density was determined by normalizing Tag to actin expression via Gene Tools from Syngene.
Nucleotide sequence accession numbers. The MM BKPyV NCCR and Tag sequencing results obtained in this study have been submitted to the GenBank database under accession no. KF445133 (BankIt1648707) and KF445132 (BankIt1648650), respectively.
RESULTS

HIVSGD-1 and HIVSGD-2 BKPyV isolation and sequence analysis.
Throat wash (TW) samples were collected from two HIVpositive subjects with diagnosed HIVSGD. To obtain kidney-derived BKPyV, urine was collected from an HIV-negative lung transplant patient with diagnosed BKPyV nephropathy (BKN). Patient demographic data (HIV status, other clinical status, age, and sex) were collected, and BKPyV viral load (VL) was determined. Whole-genome (wg) BKPyVs were cloned from each sample, and the viral NCCR promoters were sequenced (Table 1 ). All three clinical samples had high VLs ranging from 1.7 ϫ 10 5 to 1.7 ϫ 10 9 copies/ml. Similar to the laboratory strain MM, both of the HIVSGD-derived BKPyV isolates had OPQPQQS NCCR block alignments. The transplant urine sample carried BKPyV with a OPQ NCCR block alignment. The NCCR architectures of previously studied laboratory strains MM, Dunlop, and VR837 BKPyV were sequenced as a control measure and recovered correctly ( Table 1) . Alignment of the whole-genome nucleotide sequences of HIVSGD-1 and HIVSGD-2 BKPyV detected 99.9% whole-genome similarity. The three single-nucleotide differences were as follows: (i) a single-base-pair thymidine (T) deletion between sequences that encoded agnoprotein and VP2 (Fig. 1A, 1 ), (ii) a thymidine/cytidine transition (T/C) within the NCCR (Fig.  1A , 2), and (iii) a single-base-pair adenosine (A) deletion within the Tag coding sequence (Fig. 1A, 3 ). All three mutations were analyzed for potential biological significance. The T deletion located between the genes coding for agnoprotein and VP2 was assumed to be least important, since this mutation did not affect either of the adjacent VP2 and agnoprotein open reading frames (Fig. 1B) . The HIVSGD-1 and HIVSGD-2 NCCRs differed by a T/C transition located within the S block of the viral promoter. To assess the potential biological significance of this nucleotide transition, putative human transcription factor binding sites (TFBS) were predicted within this region of the NCCR. Identical TFBS (Smad3, Smad4, C/EBP␣, AP-2␣A, and E47) were predicted for both HIVSGD-1 and HIVSGD-2 ( Fig. 2A) . Next, in vitro promoter activity was assessed to determine whether the transition led to differential promoter activity despite homologous TFBS. HIVSGD-1 and HIVSGD-2 NCCR-pGL3 reporter constructs were generated in the early and in the late directions. NCCR reporter and pGL3 basic control constructs were cotransfected with (black bars) and without (white bars) full-length VR837-derived Tag in HSG cells (Fig. 2B and C) . Promoter activity was determined as fold luciferase (Luc) induction over pGL3-Basic. Tag protein expression was confirmed by immunoblot analysis. Similar promoter activity levels were achieved for both HIVSGD-1 and HIVSGD-2 in the early direction, independent of Tag's presence or absence: 2.7-versus 2.4-fold and 12-versus 11.4-fold induction, respectively (Fig. 2B) . HIVSGD-2 promoter activity was higher than that of HIVSGD-1in the late direction independent of Tag's presence or absence: 54-versus 31-fold and 7-versus 2-fold induction, respectively (Fig. 2C) . Overall, NCCR activity differences between HIVSGD-1 and HIVSGD-2 were nominal. Functional Tag is known to suppress the BKPyV NCCR in the early direction and induce it in the late direction (4) . Hence, the observations made here suggested that the cloned HIVSGD NCCRs were functional within the reporter constructs.
The adenosine (A) deletion detected within the Tag nucleotide sequence of HIVSGD-2 but not within HIVSGD-1 was analyzed for potential biological significance (Fig. 3A) . ClustalW (47)-based Tag amino acid sequence alignment of HIVSGD-1, HIVSGD-2, and the simian virus 40 (SV40) pRb binding domain (1GH6:ChainA) located the deletion distal to the pRb binding site of the Tag viral protein and detected 82.5% sequence identity between SV40 and HIVSGD-1 full-length Tag. The deletion was predicted to introduce an early stop codon that truncated the original Tag nuclear translocation signal from PKKKRKV to PKKKER (Fig. 3B ). HIVSGD-2 Tag, which carried the early stop codon, was calculated to express a Tag mutant of 15.6 kDa instead of the 80.5-kDa full-length Tag expressed by BKPyV HIVSGD-1 (Fig.  3C) . A schematic model of full-length HIVSGD-1 and truncated HIVSGD-2 Tag was created using the HHPred and MODELLER structural prediction tools (48) . This truncating deletion was likely the most significant of the three nucleotide mutations due to the truncation and the importance of Tag for the viral life cycle.
Assessment of HIVSGD BKPyV replication in vitro: posttransfection. The posttransfection replication potential of HIVSGD-1 and HIVSGD-2 BKPyV was assessed within human salivary gland and kidney cells (Fig. 4) . BKPyV clones of throat wash-derived HIVSGD-1 and HIVSGD-2, kidney-derived U1, and laboratory strains MM and Dunlop were used for in vitro analysis (Table 1) . Laboratory strain VR837 was used as an infectious BKPyV-positive control.
The capacity for de novo BKPyV DNA synthesis post-salivary gland cell (HSG)-transfection was determined. HSG cells were transfected with HIVSGD-1 (encoding full-length Tag), U1, MM, and Dunlop BKPyV episomes and evaluated using a restriction enzyme resistance assay. The DpnI/Sau3a enzyme resistance assay allowed discernment between transfected BKPyV genomes (methylated bacterial plasmid DNA) and BKPyV genomes made de novo (nonmethylated eukaryotic DNA). DNA was isolated 6 days posttransfection (p.t.), digested with DpnI and Sau3a, and visualized by Southern blotting (Fig. 5 ). DpnI and Sau3a cleaved the same restriction sites, but DpnI digested exclusively bacterial and not eukaryotic methylation patterns, while Sau3a digestion was methylation pattern independent (9, 49) . While multiple bands were detected post-Sau3a digestion, clear differences in the While not all bands are distinct, they corresponded to mapped MM BKPyV (GenBank accession no. V01109.1) DpnI/Sau3a cut sites resulting in fragments ranging from 1 to 1.6 kb. BKPyV DNA bands between 1.6 and 5 kb are likely due to incomplete digestion, and prominent bands at ϳ5 kb (Fig. 5A, lane 7) correspond to whole-genome BKPyV, as previously reported (9) . In summary, the enzyme resistance assay suggested that both HIVSGD-1 and MM BKPyV DNA were made de novo in transfected HSG cells. The intention of this assay was not to compare BKPyV replication levels but to firmly establish that HIVSGD-1 BKPyV could replicate its DNA in human salivary gland cells. Faint kidney-derived U1 BKPyV DNA bands were visualized upon long exposure, suggesting potential replication (Fig. 5A, lanes 3 and 4) . Tag protein expression reflects successful transition through the early BKPyV life cycle. The consequence of the HIVSGD-2 Tag mutation on its protein expression was assessed. Levels of Tag CACCACCCAAAAAAAAAAGAAAGGTAGAAGACC CACCACCCAAAAAAAAA-GAAAGGTAGAAGACC MDKVLNREESMELMDLLGLERAAWGNLPLMRKA-LRKCKEFHPDKGGDEDKMKRMNTLYK 59 MDKVLNREESMELMDLLGLERAAWGNLPLMRKA-LRKCKEFHPDKGGDEDKMKRMNTLYK 59 ---SHMREESLQLMDLLGLERSAWGNIPLMRKAYLKKCKEFHPDKGGDEEKMKKMNTLYK 57 ****::*********:****:****** *:*************:***:****** KMEQDVKVAHQPDFG-TWSSSEVPTYGTEEWESWWSSFNEKWDEDLFCHEDMFASDEEAT 118 KMEQDVKVAHQPDFG-TWSSSEVPTYGTEEWESWWSSFNEKWDEDLFCHEDMFASDEEAT 118 KMEDGVKYAHQPDFGGFWDATEIPTYGTDEWEQWWNAFNE---ENLFCSEEMPSSDDEAT 114 ***:.** ******* *.::*:*****:***.**.:*** *:*** *:* :**:*** ADSQHSTPPKKKRKVEDPKDFPSDLHQFLSQAVFSNRTLACFAVYTTKEKAQILYKKLME 178 protein expression were determined 5 days post-HSG transfection and compared among clinical isolates HIVSGD-1, HIVSGD-2, and U1 and laboratory strain MM BKPyV by Western blotting (Fig. 6A) . The laboratory strain Dunlop BKPyV was not further assessed as HSG cells were unable to support DNA replication (Fig. 5) . The harvest time point was selected based on previous studies that detected Tag protein expression 4 days p.t. (26, 34) . Tag was normalized to expression of ␤-actin, a loading control (Fig. 6B) . The highest Tag expression was detected for HIVSGD-1 (full-length, ϳ80 kDa), followed by MM and U1 BKPyV (Fig. 6B) . Both full-length and truncated (ϳ15 kDa [not shown]) forms of Tag protein were below the level of immunoblot detection for HIVSGD-2. No Tag protein was detected in mock-infected negative controls.
To further evaluate the replication potential of each isolate, encapsulated BKPyV virions released from transfected HSG cells were quantified. At 6 days p.t., BKPyV viral loads (VLs) of filtered and DNase-treated media from transfected HSG cells were determined by quantitative real-time PCR (qPCR). The supernatant of all BKPyV-transfected HSG cells carried encapsulated BKPyV DNA. MM-and HIVSGD-1-transfected HSG cells supported similarly high VLs, with 3.5 ϫ 10 7 and 2.4 ϫ 10 7 copies/l, respectively. U1 and HIVSGD-2 VLs were significantly lower than that of HIVSGD-1, at 1.4 ϫ 10 3 and 2.6 ϫ 10 2 copies/l, respectively (Fig.  7A) . Differences between HIVSGD-2 and U1 VLs each compared to HIVSGD-1 were highly statistically significant (P ϭ 0.0001). HIVSGD-1 was the most efficient replicator, followed by MM, U1, and HIVSGD-2. Interestingly, low levels of HIVSGD-2 virions were detected, despite the Tag mutation and lack of Tag expression, as described above. To confirm the presence of BKPyV virions, HSG supernatant (6 days p.t.) was analyzed by transmission electron microscopy (TEM). BKPyV particles were detected by TEM for HIVSGD-1 and MM but were not detected for lower replicators U1 or HIVSGD-2 BKPyV (Fig. 7B) . Morphological features of HIVSGD-1 and MM BKPyV were reminiscent of icosahedral (T ϭ 7) symmetrical BKPyV particles with a diameter of 45 nm (4) that have been visualized in in vitro-derived supernatants (34) and patient-derived fluids (50) . The titer of infectious HSG transfection-derived BKPyV virions was determined via the fluorescent focus assay (FFA). FFA provided antibody-based detection of intracellular PyV proteins postinfection (44) . Vero cells were exposed to HSG cell supernatant containing BKPyV and incubated for 4 days, and infected cells were quantified. Intracellular PyV structural proteins (VP1, VP2, and VP3 [green]) were detected for HIVSGD-1, HIVSGD-2, and laboratory strain MM but not for U1 BKPyV or mock infection (Fig. 8) . As in previous studies (44) , PyV proteins were detected exclusively in the nucleus (DAPI [blue]) of infected Vero cells (Fig. 8C) . Infectious BKPyV VR837, which has been shown to replicate permissively in HSG and Vero cells (26) served as a positive control. HIVSGD-1, MM, and HIVSGD-2 scored 80, 50, and 1 FFU/l, respectively. HIVSGD-1 infected significantly more cells than laboratory strain MM (P ϭ 0.01) and HIVSGD-2 (P ϭ 0.0001) (Fig. 8B) . Despite detectable U1 VLs by qPCR, U1 BKPyV intracellular proteins were not detected by FFA.
Clinical and laboratory strain BKPyV postinfection. Infections were performed to assess cell-type-dependent reproduction of HSG-derived BKPyV (Fig. 4, part 2 ). HSG and Vero cells were simultaneously infected with equal amounts of BKPyV that originated from HSG cell transfections-an equivalent of 200 FFU for each viral substrain (Fig. 4, part 1) . Encapsulated BKPyV virions released from infected HSG and Vero cells were quantified by qPCR at 2, 4, 6, and 8 days postinfection (p.i.). HIVSGD-1 and MM BKPyV VLs increased by 4 and 3 orders of magnitude, respectively, in HSG cells over 8 days p.i. In Vero cells, HIVSGD-1 and MM BKPyV VLs increased by 5 and 4 orders of magnitude, respectively, over 8 days p.i. (Fig. 9A) . These results indicated that HSG cell transfection-derived HIVSGD-1 and MM BKPyV were infectious and underwent replication in both HSG and Vero cells. Encapsulated HIVSGD-2 and U1 BKPyV DNAs were not detected from either cell type. Interestingly, the VL kinetics of BKPyV in Vero and HSG cells were similar upon infection, suggesting that virion production was equally efficient in both HSG and Vero cells (Fig. 9B ). U1 and HIVSGD-2 virions were not identified upon inspection. MM BKPyV-infected HSG cell medium was not analyzed by TEM.
The infectivity of HSG-and Vero cell-derived BKPyV progeny was assessed by FFA (Fig. 10) . Vero cells were infected with HSG and Vero cell media 8 days p.i. and incubated over 4 days. PyV structural proteins (VP1, VP2, and VP3 [green]) were detected at 289 FFU/l for VR837 (positive control), and no viral proteins were detected in mock infections (Fig. 10A) . HSG cell infectionderived MM and HIVSGD-1 BKPyV both scored 48 FFU/l, whereas U1 scored 5 FFU/l (9.6-fold less). No infectious HIVSGD-2 BKPyV was detected (Fig. 10B) . Interestingly, much lower FFUs were detected in Vero cell infection-derived MM and HIVSGD-1 BKPyV (10 FFU/l and 19 FFU/l, respectively) than in these viruses of HSG cell origin (48 FFU/l). These results indicated that HIVSGD-1 and MM BKPyV were more infectious if originating from HSG (salivary gland) cells than Vero (kidney) cells (Fig. 10C and D) , despite the detection of similar VLs in both cell types (Fig. 9) . Most strikingly, among Vero cell-derived BKPyV, the kidney-derived virus U1 (58 FFU/l) was most infectious and displayed 5.8-fold-higher FFU/l than MM and 3-foldhigher FFU/l than HIVSGD-1 BKPyV. Despite the lack of de- tectable VLs (Fig. 9) , U1 (kidney-derived) BKPyV scored higher FFU originating from kidney (Vero) cells than salivary gland (HSG) cells (Fig. 10C and D) . As expected, the lack of measurable HIVSGD-2 BKPyV VL was associated with an inability to detect infected cells, whether Vero or HSG cell derived.
DISCUSSION
HIV-associated salivary gland disease (HIVSGD) is among the most significant HIV/AIDS-associated oral lesions (25) . Previously published data by our group suggested a correlation between HIVSGD and BKPyV (25, 26) . To our knowledge, we are the first to analyze HIVSGD BKPyV and to establish a fully permissive salivary gland cell culture model supporting productive replication of clinical BKPyV isolates. The present study assessed replication differences in genomically similar HIVSGD isolates and compared a kidney-derived clinical isolate to HIVSGD clinical isolates. We assessed the noncoding control region (NCCR) of these isolates and determined in vitro replication capabilities in both salivary gland and kidney cells. Importantly, this study provides evidence for differences in cell tropism based on the cell origin of BKPyV. Three clinical BKPyV isolates were characterized and compared: HIVSGD-1 and HIVSGD-2 were isolated from the throat wash (TW) samples of HIVSGD-positive patients, and U1 was isolated from the urine sample of an HIVSGD-negative transplant patient (kidney-associated isolate). BKPyV viral loads (VLs) from all three clinical samples were high and ranged from 1.7 ϫ 10 5 to 1.7 ϫ 10 9 copies/ml, likely reflecting immunosuppression in each instance. We previously established that VLs in healthy individuals and in HIV-positive patients without HIVSGD were 3 to 4 logs lower than the VLs detected in HIVSGD-positive individuals (25) . Comparable VLs in the HIVSGD-associated oral fluid samples and in the urine sample from a transplant patient diagnosed with BKN suggested a significant increase in shed virus, perhaps at pathogenic levels.
Whole-genome sequence alignment of the two HIVSGD clones (HIVSGD-1 and HIVSGD-2) determined 99.9% similarity, despite three point mutations (Fig. 1A) . A thymidine deletion was detected between the open reading frames (ORFs) that encoded agnoprotein and VP2 (Fig. 1A, bar 1) . The deletion was outside the respective ORFs and was therefore unlikely to affect replication. Nevertheless, it was possible that the mutation could have interfered with VP2 gene expression via disruption of a potential internal ribosome entry site (IRES) that was present in this region of the BKV genome. However, the affected nucleotide stretch did not contain a known IRES (Fig. 1B) .
The BKPyV NCCR is the main determinant of in vitro replication (9) , and rearrangements confer significant differences in rep- lication capacity, transforming potential, host cell permissivity, and tropism (12, 37, 39, 40, (51) (52) (53) . NCCR rearrangements are defined as changes in the NCCR block sequences compared to the archetype. The archetypic BKPyV substrain, defined by carrying the OPQRS NCCR architecture, is commonly shed in urine (5) . We sequenced the BKPyV NCCRs of the three clinical isolates and detected a common signature block alignment, OPQPQQS, among the HIVSGD TW samples. NCCR block divergence from archetype into rearranged (rr) variants, as detected in this study, have been previously recorded both in vivo (16, 51, 54, 55) and in vitro (16, 35, 37, 38, 56) . Prior studies among transplant recipients with prolonged viremia illustrated that rearranged architectures eventually became dominant over the archetype (39) . The rr NCCR OPQPQQS may reflect the dominant architecture within these HIVSGD patients and may represent a stable and biologically significant variant. Despite VP1-based classification of BKPyV genotypes (57) , BKPyV variants are categorized by NCCR block sequence (58) . The OPQPQQS NCCR block alignment was previously described in laboratory strain MM; however, to our knowledge, other clinical isolates carrying this architecture have not been reported. Importantly, underlying nucleotide differences distinguished the HIVSGD clinical isolates from MM. Inclusion of well-described BKPyV laboratory strains during NCCR genotyping corroborated the authenticity of our results.
HIVSGD-1 and MM BKPyV shared the NCCR OPQPQQS block architecture and exhibited similar levels of Tag expression, virion production, and infectivity. Similar replication efficiency between HIVSGD-1 and MM may be explained by the analogous NCCR architecture. HIVSGD-2, however, consistently lacked signs of efficient in vitro replication. While HIVSGD-2 shared the overall NCCR architecture with HIVSGD-1 and MM, the HIVSGD-2 NCCR S block contained a thymidine (T)/cytidine (C) transition (Fig. 1A, no. 2 ). This NCCR transition did not lead to differential prediction of putative human TFBS ( Fig. 2A) or to differences in the early promoter activity in the presence or absence of full-length Tag (Fig. 2B) and thus was an unlikely contributor to differences in replication efficiency. Interestingly, the HIVSGD-2 promoter in the late direction was induced more readily, in the presence or absence of full-length Tag, than the high replicator HIVSGD-1 (Fig. 2C) . Based on in vitro results that characterized HIVSGD-2 as an inefficient replicator, higher HIVSGD-2 promoter activity in the late direction was unlikely to affect its viral fitness. Despite the well-documented importance of the NCCR for BKPyV replication, the S block point mutation appeared unlikely to affect viral fitness.
Inefficient HIVSGD-2 replication was likely associated with the adenosine deletion distal to the Tag pRb binding domain. This point mutation was predicted to introduce an early stop codon and modify the nuclear translocation signal (Fig. 3A and B) . This resulted in the expression of a truncated form of Tag that decreased the predicted Tag protein size from 80.5 kDa to 15.6 kDa. The mutant form of Tag lost the origin-binding domain (OBD), p53 site, and ATP/helicase domain (Fig. 3C) and carried a modified version of the nuclear translocation signal (Fig. 3A and B) . Tag is central to genome replication and PyV life cycle completion (59) (60) (61) . Insufficient Tag expression has been shown to impede archetypic BKPyV replication in vitro (34) . It is therefore likely that insufficient Tag expression dramatically inhibited HIVSGD-2 replication. Remarkably, the isolation of HIVSGD-2 BKPyV from the TW sample and generation of progeny virus served as evidence of minimal HIVSGD-2 replication both in vivo and in vitro. HIVSGD-2 virus was detected at low levels posttransfection, as determined by qPCR (VL measurement in Fig. 7) , and was infectious, as measured by FFA (Fig. 8) . Two potential mechanisms may have allowed for low levels of HIVSGD-2 replication. (i) In vivo, the first mechanism is provision of Tag in trans by other BKPyV substrains. Broekema et al. demonstrated that provision of overexpressed Tag allowed the cultivation of archetype BKPyV, a typically low in vitro replicator (34) . (ii) In vitro and in vivo, by the second mechanism, low levels of full-length Tag could be produced by ribosomal frameshifting. Ribosomal frameshifting commonly takes place in retroviruses facilitated by a slippery A/T-rich heptanucleotide sequence that allows for low protein expression despite the presence of a stop codon (62) . The A/T-rich stretch within HIVSGD-2 BKPyV Tag located 5= to the stop codon may allow for frameshifting in the context of BKPyV. Moreover, premature truncations of Tag have been detected in other PyVs. Merkel cell polyomavirus (MCV) mutations that prematurely truncated Tag were found in strains derived from human tumors but not in benign sources and have been postulated to render MCV more malignant (60) . Likewise, there is the potential that truncation of HIVSGD BKPyV Tag not only may decrease replication efficiency but also may be associated with increased in vivo transformation potential.
HIVSGD BKPyV in vitro viability was assessed by transfection (Fig. 4, part 1) and infection (Fig. 4, part 2 ) of salivary gland cells and kidney cells. Kidney cells represented the historically described replication niche. HIVSGD BKPyV fitness was compared to those of both kidney-derived substrain U1 and laboratory strain MM (Table 1) . We hypothesized that shed HIVSGD isolates were likely to replicate in salivary gland cells in vivo, and by extension, these isolates would replicate efficiently within HSG cells in vitro. Indeed, HIVSGD-1 consistently exhibited high replication competence in salivary gland cells. HIVSGD-1 and MM demonstrated the highest posttransfection replication efficiency compared to HIVSGD-2 and kidney-derived U1, as determined by viral protein concentrations (Fig. 6) , VLs (Fig. 7) , and significant levels of infectious BKPyV progeny (Fig. 8) . Furthermore, the high replication capability of HIVSGD-1 was consistent during infection of HSG and Vero cells (Fig. 4, part 2 ) with high levels of HSG cell-released progeny virus (Fig. 9) . HIVSGD-1, MM, and U1 but not HIVSGD-2 completed a full life cycle upon secondary viral passage.
HIVSGD-1 and MM VL measurements suggested equally efficient levels of virion production upon infection of HSG and Vero cells, as the replication kinetics were very similar (Fig. 9) . Differences in scored infectious units, however, suggested that while replication kinetics and progeny output were consistent for HIVSGD-1 and MM, subsequent infectivity was distinct, depending on cell type and virus origin comparing HIVSGD-1 or MM versus kidney-derived U1 (Fig. 10D) . When HIVSGD-1 and MM BKPyV originated from HSG cells rather than Vero cells higher FFU were scored. Likewise, when kidney-derived U1 BKPyV originated from Vero cells rather than HSG cells, higher FFU were scored. Differential infectivity suggested HIVSGD BKPyV displayed preferential tropism for salivary gland cells over kidney cells. Similarly, U1 displayed preferential tropism for kidney cells over salivary gland cells. Additionally, we recorded a dramatic increase in viral progeny production for Vero cell-derived U1 during the 4-day Vero cell incubation for the FFA (Fig. 10) . This was interesting since U1 VLs were below the level of detection for qPCR quantification at 8 days p.i. (Fig. 9 ) and suggested that kidney-derived U1 BKPyV was able to produce infectious progeny more efficiently in kidney cells (58 FFU/l) than HSG cells (5 FFU/l) (Fig. 10) . Overall, differential infectivity depending on cell origin suggested that U1 displayed kidney tropism and HIVSGD BKPyV displayed salivary gland tropism, consistent with their respective in vivo kidney and salivary gland origins. Interest-ingly, previous studies comparing levels of laboratory strain BKPyV replication among a wide range of different cell lines detected few differences in replication potential and did not indicate specific cellular tropisms (63, 64) . These studies assessed over 60 cell types: among them were lung-, colon-, central nervous system (CNS)-, ovary-, renal-, and bladder-derived cell lines. Salivary gland cells were not assessed.
BKPyV isolated from the TW of HIVSGD patients is likely relevant to disease in the in vivo setting and has now undergone initial in vitro characterization. High BKPyV VLs were detected in the oral fluids of two individuals diagnosed with HIVSGD. We identified a common NCCR block architecture among HIVSGDderived BKPyV isolates and successfully cultured clinical HIVSGD-derived BKPyV in human salivary gland cells and in kidney cells. Our assessment of a high-replication clinical isolate and a low-replication clinical isolate suggested that a single point mutation in Tag brought about the stark differences in the in vitro replication potential. The high replicator (HIVSGD-1) surpassed the replication potential of the kidney-derived isolate (U1) in human salivary gland cells, replicated efficiently in human salivary gland and kidney cells, and displayed signs of salivary gland tropism.
Our results are significant, as they corroborate a potential connection between BKPyV and HIVSGD and provide an important initial understanding of BKV replication in the oral compartment. Our data suggest that HIVSGD TW-derived BKPyV displays preferential tropism for salivary gland cells, and we have now proven that wild-type oral-clinical BKV isolates undergo permissive replication in salivary gland cells in vitro. Permissive replication of wild-type clinical BKV isolates previously thought to occur predominately in renal epithelium and uro-epithelium may be ongoing at other sites as well. Saliva serves as a transmission vehicle for many microorganisms, and our data corroborate previous data showing that the oral compartment and saliva may function as a transmission vehicle for BKPyV in vivo as well. The small number of characterized HIVSGD isolates is a clear limitation of this current study and thus may not be representative of all HIVSGD variants. A study encompassing a larger number of isolates would be more representative and needs to be performed. Importantly, this study provides a system for the study of clinical oral BKPyV infection, and these observations provide insights for future BKPyV pathogenesis, transmission, and disease association studies.
